C12N 2760/10134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/10134 (Use of virus or viral component as vaccine) appears on 7 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 11
- Assignees
- 6
- Inventors
- 17
- Latest grant
- 25 Oct 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes25 Oct 2022US 11,478,544 B2Svenska Vaccinfabriken Produktion AB
- Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes2 Feb 2021US 10,905,760 B2Svenska Vaccinfabriken Produktion AB
- Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection5 Jun 2018US 9,987,352 B2GlobeImmune, Inc.
- Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection28 Feb 2017US 9,579,377 B2GlobeImmune, Inc.
- Ribozyme compositions and expression vectors30 Jun 1998US 5,773,260 AInnovir Laboratories, Inc.
- Compositions and methods for treating and preventing hepatitis b and d19 Jun 2025US 2025/0197452 A1SVF Vaccines AB
- Methods and systems for diagnosing orthopoxvirus infection8 May 2025US 2025/0147043 A1
- Lassa virus vaccine and uses thereof11 Jul 2024US 2024/0226265 A9Inovio Pharmaceuticals, Inc.
- Lassa virus vaccine and uses thereof25 Apr 2024US 2024/0131143 A1Inovio Pharmaceuticals, Inc.
- Compositions and methods for treating and preventing hepatitis b and d16 Mar 2023US 2023/0079898 A1Svenska Vaccinfabriken Produktion AB
Most cited
By later US patents
- Therapeutic ribozyme compositions and expression vectors92US 5,225,347 AInnovir Laboratories, Inc. · 1993
- Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection3US 9,579,377 B2GlobeImmune, Inc. · 2017
- Ribozyme compositions and expression vectors2US 5,773,260 AInnovir Laboratories, Inc. · 1998
- Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes1US 10,905,760 B2Svenska Vaccinfabriken Produktion AB · 2021
- Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection1US 9,987,352 B2GlobeImmune, Inc. · 2018